Safety and Feasibility of CIK Cell Therapy in HCC After Tumor Resection

Inclusion Criteria: * Age between 18 and 80 years * Documented HCC at BCLC stage 0-A, having undergone surgical tumor resection * Single tumor or ≤3 nodules, each ≤3 cm * Child-Pugh score A-B * ECOG performance status 0-1 * Confirmed cancer-free status one month after surgery * Written informed consent * Leukocyte count \> 3 × 10⁹/L * Absolute neutrophil count (ANC) ≥ 1,000/µL * Hemoglobin ≥ 8.5 g/dL * Platelet count \> 50 × 10⁹/L * BUN and serum creatinine ≤ 1.5 × upper limit of normal No extrahepatic abdominal disease spread, confirmed by abdominal CT/MRI Exclusion Criteria: * Active infection or uncontrolled viremia (particularly HBV, HCV, or HIV) * Any cell therapy or immunotherapy in the past 6 months, or current participation in another clinical study * Another malignancy (prior or concurrent) differing from HCC in primary site or histology * Clinically significant cardiovascular disease (e.g., heart failure, serious arrhythmia, symptomatic coronary artery disease) * History of organ transplantation * Primary or secondary immunodeficiency, or active autoimmune disease * Severe allergic disorder or history of anaphylaxis * Pregnancy or breastfeeding at study entry * Women of childbearing potential intending to become pregnant